IQVIA CFO Ron Bruehlman to Retire; Michael Fedock Named Successor

By Hao Liu • Tuesday, September 02 15:39 • Permanent Link

IQVIA Holdings Inc. has announced a planned leadership transition in its finance organization. Michael Fedock, currently Senior Vice President of Financial Planning & Analysis, has been appointed Executive Vice President and Chief Financial Officer, effective February 28, 2026. He will succeed Ron Bruehlman, who will retire as CFO after a distinguished tenure.

Ron Bruehlman joined IQVIA in 2011 when he joined IMS Health as CFO. He played a key role in the Initial Public Offering of IMS Health in 2014 and the successful merger of Quintiles and IMS Health in 2016. He returned from retirement in 2020 to support IQVIA during a critical period, including navigating the COVID-19 pandemic and building a high-performing global finance organization.

Mr. Bruehlman’s successor, Michael Fedock, joined IQVIA in 2016 and has held several senior financial roles, including CFO of IQVIA’s Research & Development Solutions business unit and CFO of IQVIA Laboratories. Prior to joining IQVIA, he served in various leadership roles at ICON plc and other healthcare organizations.

Mr. Fedock holds a Master of Business Administration from the University of Baltimore and a Bachelor of Science in Biological Sciences from Drexel University. He expressed his privilege in taking on the role of CFO at IQVIA and looks forward to continuing to work with the CEO to drive IQVIA’s strategic growth and shareholder value creation.

Ron Bruehlman commented that it has been an honor to serve as CFO of IQVIA and looks forward to supporting the leadership team during this transition and beyond as IQVIA continues to execute on its long-term strategy.

IQVIA is a leading global provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries. With approximately 90,000 employees in over 100 countries, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. Today the company's shares have moved -3.41% to a price of $184.295. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.